Kei Muro
Active 1997–2025
- 178
- Papers
- 38,056
- Citations
- 81
- h-index
- 170
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine75.4%
- Biochemistry, Genetics and Molecular Biology14.4%
- Materials Science3.5%
- Immunology and Microbiology3.4%
- Pharmacology, Toxicology and Pharmaceutics0.9%
- Neuroscience0.7%
- Other1.7%
Topics
- Cancer Immunotherapy and Biomarkers9.9%
- Gastric Cancer Management and Outcomes7%
- Colorectal Cancer Treatments and Studies6.2%
- Esophageal Cancer Research and Treatment4.4%
- Colorectal Cancer Surgical Treatments3.3%
- Genetic factors in colorectal cancer2.4%
- Other66.8%
Coauthors
- Kohei Shitara35
- Eric Van Cutsem30
- Atsushi Ohtsu27
- Hyun Cheol Chung26
- Narikazu Boku23
- Ken Kato22
- Takayuki Yoshino22
- Shigenori Kadowaki19
- Toshihiko Doi19
- Yoshito Komatsu19
- Yung‐Jue Bang19
- Taroh Satoh18
- Zev A. Wainberg18
- Tomohiro Nishina17
- Josep Tabernero16
- Yukiya Narita16
- Charles S. Fuchs15
- Hiroki Hara15
- Hirofumi Yasui14
- Kensei Yamaguchi14
- Shuichi Hironaka14
- Hiroya Taniguchi13
- Kentaro Yamazaki13
- Masahiro Tajika13
All papers
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen‐Shi Chen, Kei Muro, Won Ki Kang, Kun‐Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun‐Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chìn, Do‐Youn Oh, Keiko Minashi, Y. Choi, Masahiro Tsuda, Li‐Tzong Chen - The Lancet 2017 cited by 2,279
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
Authors: Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I. Jalal, Manish A. Shah, Jean-Phillipe Metges, Marcelo Garrido, Talia Golan, Mario Mandalà, Zev A. Wainberg, Daniel V.T. Catenacci, Atsushi Ohtsu, Kohei Shitara, Ravit Geva, Jonathan Bleeker, Andrew H. Ko, Geoffrey Y. Ku, Philip Philip, Peter C. Enzinger, Yung‐Jue Bang, Diane Levitan, Jiangdian Wang, Minori Koshiji Rosales, Rita P. Dalal, Harry H. Yoon - JAMA Oncology 2018 cited by 1,812
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Authors: Eric Van Cutsem, Andrés Cervantes, René Adam, Alberto Sobrero, J. Han van Krieken, Dan Aderka, E. Aranda Aguilar, Alberto Bardelli, Al B. Benson, G. Bodoky, Fortunato Ciardiello, André D’Hoore, Eduardo Díaz‐Rubio, Jean‐Yves Douillard, Michel Ducreux, Alfredo Falcone, Axel Grothey, Thomas Gruenberger, Karin Haustermans, Volker Heinemann, Paulo M. Hoff, C.-H. Köhne, Roberto Labianca, Pierre Laurent‐Puig, Brigette Ma, Tim Maughan, Kei Muro, Nicola Normanno, Pia Österlund, Wim J.G. Oyen, Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 cited by 3,449
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
Authors: Yojiro Hashiguchi, Kei Muro, Yutaka Saitō, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Kiyoshi Hasegawa, Kinichi Hotta, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Yusuke Kinugasa, Keiko Nemoto Murofushi, Takako Eguchi Nakajima, Shiro Oka, Toshiaki Tanaka, Hiroya Taniguchi, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Takeharu Yamanaka, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Michio Itabashi, Kentaro Sakamaki, Keiji Sano, Yasuhiro Shimada, Shinji Tanaka, Hiroyuki Uetake, Shigeki Yamaguchi, Naohiko YAMAGUCHI, Hirotoshi Kobayashi, Keiji Matsuda, Kenjiro Kotake, Kenichi Sugihara, Japanese Society for Cancer of the Colon and Rectum - International Journal of Clinical Oncology 2019 cited by 1,958
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Authors: Takashi Kojima, Manish A. Shah, Kei Muro, Éric François, Antoine Adenis, Chih‐Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung‐Bae Kim, Se‐Hoon Lee, Jaafar Bennouna, Ken Kato, Lin Shen, Peter C. Enzinger, Shukui Qin, Paula Ferreira, Jia Chen, Gustavo Girotto, Christelle de la Fouchardière, Hélène Senellart, Raed Moh’d Taiseer Al-Rajabi, Florian Lordick, Ruixue Wang, Shailaja Suryawanshi, Pooja Bhagia, Soonmo Peter Kang, Jean‐Philippe Metges, on behalf of the KEYNOTE-181 Investigators - Journal of Clinical Oncology 2020 cited by 1,176
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Authors: H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu - The Lancet Oncology 2014 cited by 2,471
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
Authors: Japanese Society for Cancer of the Colon and Rectum, Toshiaki Watanabe, Kei Muro, Yoichi Ajioka, Yojiro Hashiguchi, Yoshinori Ito, Yutaka Saito, Tetsuya Hamaguchi, Hideyuki Ishida, Megumi Ishiguro, Soichiro Ishihara, Yukihide Kanemitsu, Hiroshi Kawano, Yusuke Kinugasa, Norihiro Kokudo, Keiko Murofushi, Takako Eguchi Nakajima, Shiro Oka, Yoshiharu Sakai, Akihito Tsuji, Keisuke Uehara, Hideki Ueno, Kentaro Yamazaki, Masahiro Yoshida, Takayuki Yoshino, Narikazu Boku, Takahiro Fujimori, Michio Itabashi, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Yasuhiro Shimada, Keiichi Takahashi, Shinji Tanaka, Osamu Tsuruta, Toshiharu Yamaguchi, Naohiko YAMAGUCHI, Toshiaki Tanaka, Kenjiro Kotake, Kenichi Sugihara - International Journal of Clinical Oncology 2017 cited by 2,490
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Authors: Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min‐Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Wasat Mansoor, Raymond S McDermott, Einat Shacham‐Shmueli, Xinqun Chen, Carlos Mayo, Soonmo Peter Kang, Atsushi Ohtsu, Charles S. Fuchs, Guillermo Lerzo, Juan Manuel O’Connor, Guillermo Ariel Mendez, James Lynam, Niall C. Tebbutt, Mark Wong, Andrew Strickland, Christos S. Karapetis, David Goldstein, Paul L. Vasey, Jean–Luc Van Laethem, Eric Van Cutsem, Scott Berry, Mark Vincent, Bettina Müller, Felipe Rey, Ángela R. Zambrano, Joaquín Guerra, Merete Krogh, Lene Bæksgaard, Mette Yilmaz, Anneli Elme, Andrus Magi, Päivi Auvinen, Tuomo Alanko, Markus Moehler, Volker Kunzmann, Thomas Seufferlein, Peter Thuss-Patience, Eray Goekkurt, Thomas Hoehler, Georg Martin Haag, Salah‐Eddin Al‐Batran, Hugo R. Castro, Karla Alejandra Lopez, Mynor Aguilar Vasquez, Mario Sandoval, Ka On Lam, Sinéad Cuffe, Cathy Kelly, Ravit Geva, Einat Shacham‐Shmueli, Ayala Hubert, Alex Beny, Baruch Brenner, Giuseppe Aprile, Alfredo Falcone, Evaristo Maiello, Rodolfo Passalacqua, Vincenzo Montesarchio, Hiroki Hara, Keisho Chìn, Tomohiro Nishina, Yoshito Komatsu, Nozumo Machida, Shuichi Hironaka, Taroh Satoh, Takao Tamura, Naotaoshi Sugimoto, Haruhiko Cho, Yashushi Omuro, Ken Kato, Masahiro Goto, Ichinosuke Hyodo, Kazuhiro Yoshida, Hideo Baba, Taito Esaki, Junji Furuse, Wan Zamaniah Wan Mohammed, Carlos Hernández Hernández, Juan Casas Garcia, Adriana Dominguez Andrade, Katriona Clarke, Geir Olav Hjortland, Nils Glenjen, Tomasz Kubiatowski, Jassem Jacek, Marek Z. Wojtukiewicz, Sergey Lazarev, Yuri Lancukhay and 58 more - The Lancet 2018 cited by 1,316
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
Authors: Joseph Chao, Charles S. Fuchs, Kohei Shitara, Josep Tabernero, Kei Muro, Eric Van Cutsem, Yung‐Jue Bang, Ferdinando De Vita, Gregory Landers, Chia‐Jui Yen, Ian Chau, Anneli Elme, Jeeyun Lee, Mustafa Özgüroğlu, Daniel V.T. Catenacci, Harry H. Yoon, Erluo Chen, David E. Adelberg, Chie‐Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg - JAMA Oncology 2021 cited by 443
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
Authors: Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H Strickler, David S Hong, Crystal S Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J Price - The Lancet Oncology 2021 cited by 288
- Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer
Authors: Jun Watanabe, Kei Muro, Kohei Shitara, Kentaro Yamazaki, Manabu Shiozawa, Hisatsugu Ohori, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino - JAMA 2023 cited by 258
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Authors: Ryan B. Corcoran, Thierry André, Chloé E. Atreya, Jan H.M. Schellens, Takayuki Yoshino, Johanna C. Bendell, Antoine Hollebecque, Autumn J. McRee, Salvatore Siena, Gary Middleton, Kei Muro, Michael S. Gordon, Josep Tabernero, Rona Yaeger, Peter J. O’Dwyer, Y. Humblet, Filip De Vos, A. Scott Jung, Jan C. Brase, Savina Jaeger, Severine Bettinger, Bijoyesh Mookerjee, Fatima Rangwala, Eric Van Cutsem - Cancer Discovery 2018 cited by 583
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Authors: Ranee Mehra, Tanguy Y. Seiwert, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Ravit Geva, Hyun Cheol Chung, Chia‐Chi Lin, Deepti Aurora-Garg, Archana Ray, Kumudu Pathiraja, Jonathan D. Cheng, Laura Q.M. Chow, Robert I. Haddad - British Journal of Cancer 2018 cited by 456
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Authors: Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel V.T. Catenacci, Shilpa Gupta, Joseph P. Eder, Talia Golan, Dung T. Le, Barbara Burtness, Autumn J. McRee, Chia‐Chi Lin, Kumudu Pathiraja, Jared Lunceford, Kenneth Emancipator, Jonathan Juco, Minori Koshiji, Yung‐Jue Bang - The Lancet Oncology 2016 cited by 1,131
- The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
Authors: Michel Ducreux, Ghassan K. Abou‐Alfa, Tanios Bekaii‐Saab, Jordan Berlin, Andrés Cervantes, Thierry de Baère, Charis Eng, Peter R. Galle, Sharlene Gill, Thomas Gruenberger, Karin Haustermans, Ángela Lamarca, Pierre Laurent‐Puig, Josep M. Llovet, F. Lordick, Teresa Macarulla, Deborah Mukherji, Kei Muro, Radka Obermannová, Juan Manuel O’Connor, Eileen M. O’Reilly, Pia Österlund, P. A. Philip, G. Prager, Erika Ruíz‐García, Bruno Sangro, Thomas Seufferlein, Josep Tabernero, Chris Verslype, Harpreet Wasan, Eric Van Cutsem - ESMO Open 2023 cited by 161
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
Authors: Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph P. Eder, Barbara Burtness, Se‐Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia‐Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled‐Filhart, Kumudu Pathiraja, Jonathan D. Cheng, Tanguy Y. Seiwert - Journal of Clinical Oncology 2016 cited by 859
- Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Authors: Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, George Pentheroudakis, Kentaro Yamazaki, Rui‐Hua Xu, Tae‐Woo Kim, Muhammad Ismail, Iain Tan, Kun‐Huei Yeh, Axel Grothey, S. Zhang, Joong Bae Ahn, M.Y. Mastura, Dawn Q. Chong, Liqun Chen, Scott Kopetz, Takako Eguchi-Nakajima, Hiromichi Ebi, Atsushi Ohtsu, Andrés Cervantes, Kei Muro, Josep Tabernero, Hironobu Minami, Fortunato Ciardiello, Jean‐Yves Douillard - Annals of Oncology 2017 cited by 592
- LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Authors: Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg, Eric Van Cutsem, Daniela Molena, Kei Muro, Woo Jin Hyung, Lucjan Wyrwicz, D-Y. Oh, Takeshi Omori, Markus Moehler, Marcelo Garrido, Sofia Oliveira, Moïshe Liberman, Victor Castro Oliden, Mehmet Bilici, John F. Kurland, Ioannis Xynos, Helen Mann, Josep Tabernero - Annals of Oncology 2023 cited by 82
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
Authors: Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie, Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki, Keita Uchino, Hirofumi Yasui, Hiroshi Tsukuda, Kazuhiro Nishikawa, Hiroyasu Ishida, Takeharu Yamanaka, Kentaro Yamazaki, Shuichi Hironaka, Taito Esaki, Narikazu Boku, Ichinosuke Hyodo, Kei Muro - Journal of Clinical Oncology 2020 cited by 197
- Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
Authors: Charles S. Fuchs, Mustafa Özgüroğlu, Yung‐Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min‐Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun Cheol Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter Thuss‐Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie‐Schin Shih, Kohei Shitara - Gastric Cancer 2021 cited by 166
- A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Authors: Toshihiko Doi, Kei Muro, Hiroshi Ishii, Terufumi Kato, Takahiro Tsushima, Mitsuhiro Takenoyama, Satoshi Oizumi, Kazuto Gemmoto, Hideaki Suna, Kouki Enokitani, Tetsuyoshi Kawakami, Hiroyoshi Nishikawa, Noboru Yamamoto - Clinical Cancer Research 2019 cited by 152
- Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer
Authors: Kohei Shitara, Kei Muro, Jun Watanabe, Kentaro Yamazaki, Hisatsugu Ohori, Manabu Shiozawa, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Ikuo Mori, Kazunori Yamanaka, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Riu Yamashita, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino - Nature Medicine 2024 cited by 110
- MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Authors: Yelena Y. Janjigian, Eric Van Cutsem, Kei Muro, Zev A. Wainberg, Salah‐Eddin Al‐Batran, Woo Jin Hyung, Daniela Molena, Michelle Marcovitz, Dario Ruscica, Scott H. Robbins, Alejandra Negro, Josep Tabernero - Future Oncology 2022 cited by 133
- A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Authors: Li‐Tzong Chen, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen‐Shi Chen, Kei Muro, Won Ki Kang, Kun‐Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun‐Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chìn, Do‐Youn Oh, Keiko Minashi, Y. Choi, Masahiro Tsuda, Hiroki Sameshima, Yoon‐Koo Kang, Narikazu Boku - Gastric Cancer 2019 cited by 231
